Dublin, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The "Advanced Renal Cell Carcinoma - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in Advanced Renal Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Renal Cell Carcinoma pipeline landscape is provided which includes the disease overview and Advanced Renal Cell Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Advanced Renal Cell Carcinoma commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Renal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Renal Cell Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Renal Cell Carcinoma.
Advanced Renal Cell Carcinoma Emerging Drugs Chapters
This segment of the Advanced Renal Cell Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Advanced Renal Cell Carcinoma Emerging Drugs
Dovitinib : Allarity Therapeutics
Dovitinib is a small molecule pan-tyrosine kinase inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR) and other receptor tyrosine kinases (RTKs). Allarity exclusively in-licensed it (globally) from Novartis. Dovitinib binds to and inhibits the phosphorylation of type III-V RTKs, such as vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) that promote tumor cell proliferation and survival in certain cancer cells. Currently, the drug is in registered stage of its development for the treatment of renal cell carcinoma.
Savolitinib: AstraZeneca/HUTCHMED
Savolitinib is an investigational small molecule inhibitor of the mesenchymal epithelial transition factor, or MET, receptor tyrosine kinase, an enzyme which has been shown to function abnormally in many types of solid tumors. The drug candidate is jointly developed in collaboration with AstraZeneca and HUTCHMED. Currently the drug is in Phase III stage of clinical trial for the treatment of renal cell carcinoma.
Ciforadenant : Corvus Pharmaceuticals
Ciforadenant is a small molecule antagonist of the adenosine A2A receptor, a key step in the adenosine pathway leading to immunosuppression in the tumor microenvironment. By precisely targeting and blocking A2A receptors on immune cells, ciforadenant may unleash their cancer-killing properties results from a Phase 1/1b clinical trial demonstrated that ciforadenant was active alone and in combination with atezolizumab in patients with advanced, refractory renal cell cancer .Currently, the drug is in Phase II stage of its development for the treatment of renal cell carcinoma.
DFF 332: Novartis Pharmaceuticals
DFF 332 is a small molecule that is HIF-2? inhibitors and targets HIF-2?(Endothelial PAS domain-containing protein 1) being developed by Novartis. The drug candidate is administered through oral route. Currently the drug is in Phase I of clinical stage for the treatment of renal cell carcinoma.
Advanced Renal Cell Carcinoma: Therapeutic Assessment
Major Players in Advanced Renal Cell Carcinoma
- There are approx. 50+ key companies which are developing the therapies for Advanced Renal Cell Carcinoma. The companies which have their Advanced Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Allarity Therapeutics
Phases
The report covers around 60+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Advanced Renal Cell Carcinoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Renal Cell Carcinoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Renal Cell Carcinoma drugs.
Advanced Renal Cell Carcinoma Report Insights
- Advanced Renal Cell Carcinoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Advanced Renal Cell Carcinoma Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Players
- Allarity Therapeutics
- AstraZeneca/HUTCHMED
- Corvus Pharmaceuticals
- Novartis Pharmaceuticals
- Adicet Bio
- CRISPR Therapeutics
- Exelixis
- Kura Oncology
- AstraZeneca
- NiKang Therapeutics
- Argos Therapeutics
- Infinity Pharmaceuticals
- Apollomics/Chia Tai Tianqing Pharmaceutical Group
- Janux Therapeutics
- OncoArendi Therapeutics
Key Products
- Dovitinib
- Savolitinib
- Ciforadenant
- DFF332
- ADI 270
- CTX 130
- Cabozantinib + Nivolumab + Ipilimumab
- Zanzalintinib
- KO-2806
- Tremelimumab
- NKT 2152
- CMN-001
- IPI-549
- TQB2450
- JANX 008
- OATD-02
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ttfuln
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
